Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPSOTCMKTS:IMUCDOTCMKTS:NSPXOTCMKTS:VVUSQOTCMKTS:WWHC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPSCapstone Therapeutics$1.80+7.8%$1.87$1.58▼$16.18$260K-0.8324,747 shs221,699 shsIMUCDImmunoCellular Therapeutics$0.07-34.0%$0.11$0.16▼$0.51$281K1.636,605 shs1,917 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsVVUSQVIVUS$0.12$0.12$0.07▼$4.55N/AN/AN/AN/AWWHCW World$0.80$0.80$0.80▼$0.80N/A0.7N/AN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPSCapstone Therapeutics0.00%-5.11%-8.24%-30.71%+166,999,900.00%IMUCDImmunoCellular Therapeutics+9.02%-35.67%-41.14%-56.57%-61.15%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%VVUSQVIVUS0.00%0.00%0.00%0.00%0.00%WWHCW World0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPSCapstone TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMUCDImmunoCellular TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVVUSQVIVUSN/AN/AN/AN/AN/AN/AN/AN/AWWHCW WorldN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPSCapstone Therapeutics 0.00N/AN/AN/AIMUCDImmunoCellular Therapeutics 0.00N/AN/AN/ANSPXInspyr Therapeutics 0.00N/AN/AN/AVVUSQVIVUS 0.00N/AN/AN/AWWHCW World 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPSCapstone Therapeutics$44.88M0.01N/AN/A($19.40) per share-0.09IMUCDImmunoCellular TherapeuticsN/AN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/AVVUSQVIVUSN/AN/AN/AN/AN/AN/AWWHCW WorldN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPSCapstone Therapeutics-$2.56MN/A0.00∞N/AN/AN/AN/AN/AIMUCDImmunoCellular Therapeutics-$14.31MN/A0.00∞N/AN/AN/AN/AN/ANSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/AVVUSQVIVUSN/AN/A0.00∞N/AN/AN/AN/AN/AWWHCW WorldN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPSCapstone TherapeuticsN/AN/AN/AN/AN/AIMUCDImmunoCellular TherapeuticsN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/AVVUSQVIVUSN/AN/AN/AN/AN/AWWHCW WorldN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPSCapstone Therapeutics0.281.140.47IMUCDImmunoCellular TherapeuticsN/AN/AN/ANSPXInspyr TherapeuticsN/A0.090.09VVUSQVIVUSN/AN/AN/AWWHCW WorldN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPSCapstone Therapeutics2.55%IMUCDImmunoCellular TherapeuticsN/ANSPXInspyr Therapeutics0.02%VVUSQVIVUSN/AWWHCW WorldN/AInsider OwnershipCompanyInsider OwnershipCAPSCapstone Therapeutics42.80%IMUCDImmunoCellular Therapeutics3.28%NSPXInspyr Therapeutics0.02%VVUSQVIVUS12.00%WWHCW World61.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPSCapstone Therapeutics38160,00090,000N/AIMUCDImmunoCellular Therapeutics34.19 millionN/ANot OptionableNSPXInspyr Therapeutics1543.15 millionN/ANot OptionableVVUSQVIVUS57N/AN/ANot OptionableWWHCW World2N/AN/ANot OptionableVVUSQ, IMUCD, NSPX, CAPS, and WWHC HeadlinesRecent News About These CompaniesCanada celebrates as Poulin lifts squad to golden glory at women’s worldsSeptember 1, 2021 | sportsnet.caS2 Saskatchewan referees earn their stripes at Women’s World Hockey ChampionshipAugust 31, 2021 | globalnews.caGFive storylines to watch as Canada, USA battle for gold at women’s worldsAugust 31, 2021 | sportsnet.caSCanada tops Switzerland, will meet U.S. in women’s world championship finalAugust 31, 2021 | sportsnet.caSU.S. blanks Finland to advance to women’s world hockey championship finalAugust 30, 2021 | sportsnet.caSRussia downs Germany at women’s world hockey championshipAugust 29, 2021 | sportsnet.caSCanadian women’s team savours Olympic preparation after pandemic disruptionAugust 29, 2021 | sportsnet.caSSwitzerland rallies to stun ROC in women’s hockey worlds quarterfinalsAugust 28, 2021 | sportsnet.caSCanadian women’s hockey team forward Turnbull turns page on disappointmentAugust 28, 2021 | sportsnet.caSCzech Republic blanks Germany to win Group B at women’s worldsAugust 25, 2021 | sportsnet.caSFinland blanks Russia for first win of women’s world hockey championshipAugust 25, 2021 | sportsnet.caSPoulin ‘doing well’ after leaving Canada’s win over Swiss with injuryAugust 25, 2021 | sportsnet.caSIIHF Women’s World Championships - How to Watch on August 22 | Channel, Stream, TimeAugust 24, 2021 | mlive.comMGermany, Czech Republic stay undefeated at women’s hockey worldsAugust 24, 2021 | sportsnet.caSIIHF expected to schedule another women’s world hockey championship in 2022August 23, 2021 | sportsnet.caSHilary Knight ties women’s world championship goal record as U.S. beats FinlandAugust 22, 2021 | sportsnet.caSSarah Fillier finds her footing with Canadian women’s hockey teamAugust 21, 2021 | sportsnet.caSCONCACAF announces two new major women's soccer tournamentsAugust 21, 2021 | tsn.caTU.S. shuts out Switzerland to open women's world hockeyAugust 21, 2021 | sportsnet.caSSting in action; Jericho, MJF finally meet in grudge match on TSN2August 20, 2021 | tsn.caTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVVUSQ, IMUCD, NSPX, CAPS, and WWHC Company DescriptionsCapstone Therapeutics NASDAQ:CAPS$1.80 +0.13 (+7.78%) As of 04:00 PM EasternCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.ImmunoCellular Therapeutics OTCMKTS:IMUCD$0.07 -0.03 (-34.02%) As of 06/27/2025ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.Inspyr Therapeutics OTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.VIVUS OTCMKTS:VVUSQ$0.12 0.00 (0.00%) As of 12/17/2020VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.W World OTCMKTS:WWHC$0.80 0.00 (0.00%) As of 04/22/2024W World Corp., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders. The company focuses on the disorders of the brain-gut axis, pain/inflammation, and autoimmune, as well as gout disorders. Its lead compounds under clinically development include Levotofisopam, a non-sedating agent for the treatment of Gout; and Dextofisopam, a non-serotonergic agent, which has completed Phase IIa and Phase IIb clinical trials for the treatment of irritable bowel syndrome. The company was founded in 1990 and is headquartered in North Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
